Pre-Filled Syringes West Coast 2021

SMi Group 14 - 15 June 2021, San Diego, USA.
Following the success of the last event, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development, device design, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future.

With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, this year's agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies, case studies on device design and complex formulation, life cycle and control strategies, and innovations in connectivity and digital health.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more. PLUS, two interactive post conference workshops:

Workshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements

Hosted by Shannon Clark, Principal, UserWise, Inc.

Workshop B: Postmarket safety reporting: The current regulatory environment with a global impact

Hosted by Khaudeja Bano, Sr. Medical Director, Abbott Molecular

Featured speakers

  • Brittney Pachucki, Device Engineer, AstraZeneca
  • Darin Zehrung, Global Program Leader, Medical Devices and Health Technologies, PATH
  • Jace Blackburn, Smart Device Engineer, Genentech
  • James P. Wabby, Executive Director, Regulatory Affairs - Device/Combination Products, Allergan
  • Jian Liu, Senior Scientist, Amgen
  • Khaudeja Bano, Senior, Medical Director, Abbott Diagnostics
  • Larry Atupem,  Sr Business Development Specialist, Zeon 
  • Maggie Reiff, Manager, Device Engineering, Pfizer
  • Mark DeStefano, Assoc. Dir. CPD Feasibility, New Technology and Prototyping Development, Teva Pharmaceuticals
  • Natalie Abts, Head of Human Factors Engineering, Genentech
  • Robert Ovadia, Engineer II, Genentech
  • Sarah Mollo, Combination Product Policy Analyst, FDA
  • Severine Duband, Global Category Manager, Nemera
  • Shannon Clark, Principal, UserWise, Inc.
  • Takuya Minezaki, Research Manager, Mitsubishi Gas Chemical Company, Inc.
  • Tina Rees, Associate Director - Human Factors, Ferring Pharmaceuticals
  • Tracy Hsu, Associate Director, Ionis Pharmaceuticals

Key reasons to attend

  • Engage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery
  • Discuss show to optimise current processes to align with global regulatory updates
  • Delve into human factors engineering best practices
  • Uncover how industry is incorporating connectivity and digital health to optimise the user experience

Who should attend

Drug-delivery developers, Medical Device Engineers, Primary Packaging material designers, Secondary packagers, Smart device developers, Training device developers, Device-safety solution providers, Drug developers.

Early bird deadlines

  • Register by 31st March to save $200
  • Register by 30th April to save $100

For further information and to register, please visit:
http://www.prefilled-syringes-westcoast.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...